中外医学研究2016，Vol.14Issue(22)：6-8,3.DOI:10.14033/j.cnki.cfmr.2016.22.003
β1受体阻滞剂对于慢性阻塞性肺疾病患者合并缺血性心脏病的疗效和安全性评价
Evaluation of Curative Effect and Safety ofβ1 Receptor Blockers in Patients with Diagnosis of the Chronic Obstructive Pulmonary Disease with ;Coronary Heart Disease
铭勇 1王玉娥 1张华 1白玛乔 1卓嘎 1秋英 1张树琼1
作者信息
- 1. 林芝市人民医院 西藏 林芝 860100
- 折叠
摘要
Abstract
Objective:To observe the curative effect and safety ofβ1 receptor blockers in patients with chronic obstructive pulmonary disease(COPD) and coronary heart disease(CHD).Method:Eighty-eight patients with the diagnosis of COPD and CHD were selected for this study,who were used to be hospitalized in our department from March 2011 to February 2015,all of them were randomly divided into control group and treatment group.The control group was prescribed the routine therapy,the treatment group were given conventional therapy plus metoprolol sustained-release tablets.The pulmonary function,B type natriuretic peptide(BNP),acute physiology and chronic health status score (APACHEⅡ) were observed of the two groups before and after treatment.Result:After treatment, the two groups of patients with lung function,BNP and APACHEⅡscores were significantly improved than before treatment(P<0.05).After 1 month of treatment, the changes of pulmonary function in the treatment group compared with the control group,the difference was not statistically significant(P>0.05),BNP and APACHEⅡscores improved significantly compared with the control group,the difference was statistically significant(P<0.05).Pearson correlation analysis showed that the use ofβ1 receptor blockers and APACHE score,BNP levels and adverse events were negatively correlated.Conclusion:β1 receptor blockers in COPD with CHE are safely and effectively capable to improve cardiac function and do not affect lung function.关键词
慢性阻塞性肺疾病/缺血性心脏病/β受体阻滞剂Key words
Chronic obstructive pulmonary disease/Ischemic heart disease/Beta receptor blocker分类
医药卫生引用本文复制引用
铭勇,王玉娥,张华,白玛乔,卓嘎,秋英,张树琼..β1受体阻滞剂对于慢性阻塞性肺疾病患者合并缺血性心脏病的疗效和安全性评价[J].中外医学研究,2016,14(22):6-8,3.
